Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aytu BioPharma, Inc. - Common Stock (NQ:AYTU)

2.240 +0.030 (+1.36%)
Streaming Delayed Price Updated: 12:34 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Earnings Outlook For Aytu BioPharma
 
Via Benzinga
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
Via ACCESSWIRE
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Via ACCESSWIRE
Aytu BioPharma: Q3 Earnings Insights
 
Via Benzinga
A Preview Of Aytu BioPharma's Earnings
 
Via Benzinga
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
 
Via Benzinga
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
Aytu BioPharma's Return On Capital Employed Insights
 
Via Benzinga
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Via ACCESSWIRE
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
Via ACCESSWIRE
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by over 400 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
Via ACCESSWIRE
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Via ACCESSWIRE
AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates
AYTU stock earnings show Aytu Biopharma missing earnings per share and revenue estimates for the fiscal third quarter. 
Via InvestorPlace
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Via ACCESSWIRE
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Gainers Leju Holdings Limited (NYSE: LEJU) gained 103.7% to $7.25 in pre-market trading after jumping around 97% on Monday . 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! 
Via InvestorPlace
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
Via ACCESSWIRE
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.